HTR4: 5-hydroxytryptamine receptor 4
G protein-coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen.
- Drugs that act on it: 16
- Approved: 4
- In phases 1 to 3: 12
- Sponsors: 11
Who is on it, and how far along
Every drug ChEMBL records acting on HTR4, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 16
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Takeda Pharmaceuticals USA319%
- Alfasigma16%
- Alizyme16%
- ANI Pharmaceuticals16%
- Dr. Falk Pharma GmbH16%
- Epix Pharmaceuticals, Inc.16%
- GSK16%
- IlDong Pharmaceutical Co Ltd16%
- Johnson & Johnson16%
- SK16%
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 12 of 16 act as: Serotonin 4 (5-HT4) receptor agonist; the rest name their own mechanism.| MetoclopramideBoxed warning | Approved | ANI Pharmaceuticals | Small molecule | Agonist | 20 |
| Prucalopride | Approved | Takeda Pharmaceuticals USA | Small molecule | Agonist | 9 |
| CisaprideWithdrawn Boxed warning | Approved | Johnson & Johnson | Small molecule | Agonist | 0 |
| TegaserodWithdrawn | Approved | Alfasigma | Small molecule | Partial agonistSerotonin 4 (5-HT4) receptor partial agonist | 0 |
| Mosapride | Phase 3 | IlDong Pharmaceutical Co Ltd | Small molecule | Agonist | 4 |
| Renzapride | Phase 3 | Alizyme | Small molecule | Agonist | 0 |
| Levosulpiride | Phase 2 | — | Small molecule | Agonist | 1 |
| Capeserod | Phase 2 | — | Small molecule | Partial agonistSerotonin 4 (5-HT4) receptor partial agonist | 0 |
| Clebopride | Phase 2 | — | Small molecule | Agonist | 0 |
| Felcisetrag | Phase 2 | Takeda Pharmaceuticals USA | Small molecule | Agonist | 0 |
| Naronapride | Phase 2 | Dr. Falk Pharma GmbH | Small molecule | Agonist | 0 |
| Piboserod | Phase 2 | GSK | Small molecule | AntagonistSerotonin 4 (5-HT4) receptor antagonist | 0 |
| PRX-03140 | Phase 2 | Epix Pharmaceuticals, Inc. | Small molecule | Partial agonistSerotonin 4 (5-HT4) receptor partial agonist | 0 |
| Relenopride | Phase 2 | SK | Small molecule | Agonist | 0 |
| Revexepride | Phase 2 | Takeda Pharmaceuticals USA | Small molecule | Agonist | 0 |
| Velusetrag | Phase 2 | Theravance Biopharma | Small molecule | Agonist | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 21 in all, from ClinicalTrials.gov.Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Schizophrenia
- 0.61
- Constipation disorder
- 0.59
- Post operative nausea and vomiting
- 0.56
- Dyspepsia
- 0.54
- Gastrointestinal disease
- 0.53
- Gastroesophageal reflux disease
- 0.53
- Gastroparesis
- 0.49
- Hypertensive disorder
- 0.49
- Nausea
- 0.47
- Vomiting
- 0.47
Genes and related targets
Complexes and families that share a gene with this target- Genes
- HTR4
- Related
- Serotonin (5-HT) receptor
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1875, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q13639, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets